KA
ADMS

Kerrisdale Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

Kerrisdale Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-229,347
Closed -$1.17M – 44
2019
Q3 		$1.17M Hold
229,347
– – 0.74% 22
2019
Q2 		$1.42M Buy
229,347
+160,500
+233% +$923K 0.51% 21
2019
Q1 		$490K Hold
68,847
– – 0.09% 30
2018
Q4 		$588K Sell
68,847
-3,993
-5% -$51.9K 0.36% 21
2018
Q3 		$1.46M Hold
72,840
– – 1.43% 10
2018
Q2 		$1.88M Sell
72,840
-262,701
-78% -$7.27M 0.78% 8
2018
Q1 		$8.02M Buy
335,541
+254,256
+313% +$8.02M 5.58% 7
2017
Q4 		$2.75M Sell
81,285
-682,642
-89% -$19.1M 5.58% 3
2017
Q3 		$16.2M Buy
+763,927
New +$14M 16.88% 2

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Kerrisdale Advisers's ADMS Position: Q4 2019 in Review

Kerrisdale Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 229,347 shares — an estimated $1.17M sold.

Kerrisdale Advisers first reported a position in ADMS in Q3 2017 and held it in 9 quarters. The position peaked at $16.2M in Q3 2017. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Kerrisdale Advisers reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Kerrisdale Advisers sold 229,347 Adamas Pharmaceuticals shares in Q4 2019, an estimated $1.17M.
  • Kerrisdale Advisers first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • Kerrisdale Advisers's Adamas Pharmaceuticals position peaked at $16.2M in Q3 2017.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Kerrisdale Advisers's 13F filing for Q4 2019, filed 14 Feb 2020.